1621. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer.

1622. Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire Gl Tract

1623. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy

1624. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure

1625. Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis

1626. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group

1627. Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis?

1628. The C hronic K idney D isease E pidemiology C ollaboration cystatin C (CKD-EPI-C ys C) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-C ys C equations?

1629. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study

1630. Sclerostin: a possible target for the management of cancer-induced bone disease

1631. Ambulatory blood pressure monitoring in acute stroke: pathophysiology of the time rate of blood pressure variation and association with the 1-year outcome

1632. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents

1633. Carcinosarcoma of the bladder

1634. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis

1635. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts

1636. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy

1637. Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support

1638. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors

1639. Prognostic Value of Serum $\beta$2-Microglobulin in Patients with Waldenstr{\"o}m's Macroglobulinemia Requiring Treatment

1640. High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.